U.S. Markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,799.70
    +10.00 (+0.56%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.6565%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.5220%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.3617%)
     
  • BTC-USD

    24,749.52
    +158.30 (+0.64%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

AstraZeneca AZN announced that the European Medical Agency (EMA) has authorized Vaxzevria, its COVID-19 vaccine, for use as a third/booster dose in adults in Europe. A primary two-dose vaccine regimen of Vaxzevria is already authorized for use in the EU.

Vaxzevria is now approved for use as a booster dose in adults who already completed a primary vaccination regimen with Vaxzevria or an mRNA-based COVID-19 vaccine developed by Pfizer PFE/BioNTech BNTX and Moderna MRNA, both of which are already approved in the European Union (EU).

The EMA’s authorization follows a positive review by the Committee for Medicinal Products for Human Use (CHMP), which recommended the use of a booster dose of the vaccine. The decisions by both the EMA and CHMP are based on clinical studies, which demonstrated an increase in immune response in participants who were given the booster dose. These participants had already completed a primary two-dose vaccine regimen with Vaxzevria or mRNA-based vaccines approved for use in the European Union (EU).

In the year so far, shares of AstraZeneca have risen 14% compared with the industry’s 5.1% increase.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Excluding the EU, AstraZeneca’s COVID-19 vaccine, either as a primary regimen or a booster dose or both, is already authorized for use in multiple countries across the globe. In fact, the primary vaccine series of the vaccine is granted authorization in more than 125 countries. However, AZN is yet to make a regulatory filing for Vaxzevria in the United States.

Last November, in the United States, the first booster doses of Pfizer/BioNTech and Moderna’s vaccines were granted an EUA for all adults (18 years of age and older). Later, Pfizer/BioNTech’s EUA was extended to allow the dosage in individuals aged 16-17 years and thereafter in adolescents varying from 12 years to 15 years of age. Last week, the Pfizer/BioNTech vaccine was also granted an EUA for use in kids between 5 years and 11 years of age.

In March this year, the FDA authorized a second booster dose of Pfizer/BioNTech and Moderna’s vaccines for older adults and some immunocompromised people. Pfizer/BioNTech and Moderna’s booster shots are authorized for use in adults in Europe.

AstraZeneca PLC Price

AstraZeneca PLC Price
AstraZeneca PLC Price

AstraZeneca PLC price | AstraZeneca PLC Quote

Zacks Rank

AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research